BioCentury
ARTICLE | Company News

Alexion, Ensemble Therapeutics deal

July 22, 2013 7:00 AM UTC

Ensemble partnered with Alexion to use Ensemble's Ensemblin technology to discover macrocyclic compounds against undisclosed targets selected by Alexion for ultra-rare disorders. Ensemble will receive an undisclosed upfront payment and research support. The biotech also is eligible for undisclosed milestones. Alexion will have exclusive rights to develop and commercializes any resulting candidates. Ensemblins are orally available synthetic macrocyclic compounds. The companies declined to disclose details. ...